Every 8-K that MEI Pharma, Inc. (MEIP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MEIP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MEIP filings page.
Lite Strategy, Inc. reported fiscal 2026 third quarter results, emphasizing its strategy of using Litecoin (LTC) as its primary treasury reserve asset and returning capital to shareholders. The company highlighted its active covered call options program, which has generated $0.7 million in net proceeds since October 2025.
Lite Strategy deployed covered call proceeds and 35,250 LTC to repurchase 1,629,136 shares under a broader $25 million share repurchase authorization, reflecting a focus on capital discipline and net asset value per share. Management also noted ongoing pre-clinical pharmaceutical programs as potential sources of non-dilutive capital.
The company framed recent Securities and Exchange Commission guidance indicating Litecoin exhibits digital commodity characteristics as a meaningful step toward regulatory clarity. Looking ahead, Lite Strategy plans to scale its options program, continue repurchases, and pursue strategic investments and partnerships that support broader Litecoin ecosystem growth.
Lite Strategy, Inc. reported fiscal 2026 second quarter results centered on a new, more active use of its Litecoin treasury and capital return strategy. The company began transforming its LTC holdings into a “productive reserve asset” by launching a covered call options program that generated nearly $600,000 in gross premiums in the quarter.
Management also used proceeds from these treasury operations to commence a $25 million stock repurchase program, aiming to practice disciplined capital allocation and address the discount to net asset value. As of December 31, 2025, Lite Strategy held $8.8 million in cash and cash equivalents and initiated pre-clinical R&D work on its drug candidate pipeline for potential out-licensing or sale opportunities.
Lite Strategy, Inc. reported results of its fiscal 2026 Annual Meeting held on February 12, 2026. Stockholders approved the 2026 Omnibus Equity Compensation Plan, which became effective upon approval and supports the company’s future stock-based incentive awards.
Approval of the 2026 plan also satisfied the contingency for previously disclosed Replacement Options granted to Mr. Justin J. File to purchase 455,000 shares of common stock. Stockholders elected Mr. File and Mr. Joshua Riezman as directors to terms running through fiscal 2029, approved an advisory vote on executive compensation, and ratified CBIZ CPAs as independent auditors for the fiscal year ending June 30, 2026.
At the meeting, 19,437,130 shares of common stock were represented by proxy out of 36,785,397 shares outstanding and entitled to vote, indicating substantial shareholder participation.
MEI Pharma, Inc. has changed its corporate name to Lite Strategy, Inc., effective September 10, 2025, through an amendment to its certificate of incorporation filed in Delaware. Under Delaware law, this name change did not require a stockholder vote and does not alter the rights of existing stockholders.
Beginning September 11, 2025, the company’s common stock, par value $0.00000002 per share, will stop trading on the Nasdaq Capital Market under the ticker symbol “MEIP” and will start trading under the new ticker symbol “LITS.” The company also issued a news release on September 10, 2025, to announce the new name and ticker.
MEI Pharma, Inc. entered a master loan agreement with BitGo Prime, LLC on September 3, 2025 that creates a framework for the company to borrow digital assets or cash under separately negotiated loan requests. Each loan will specify principal, fees, collateral requirements, and term; fees (the effective interest) are set and calculated daily at the annualized rate shown in each confirmation.
Borrowings under the agreement are secured by collateral that is typically required to exceed the borrowed amount and are subject to margin calls; failure to maintain collateral can lead to default remedies including collateral liquidation. The agreement also includes customary representations, covenants, and events of default. A copy of the master agreement is filed as Exhibit 10.1.
MEI Pharma, Inc. (MEIP) filed an 8-K dated August 5, 2025 reporting Regulation FD disclosure and other events related to digital asset purchases. The company acquired 929,548 Litecoin (LTC) at an average price of $107.58 during July 30–August 4, 2025, deploying all net proceeds from a PIPE private placement dated July 17, 2025. MEI states it is the first U.S.-listed public company to adopt Litecoin as a primary reserve asset and is implementing a new strategy built on digital asset infrastructure and long-term capital innovation. A press release is furnished as Exhibit 99.1. The filing does not disclose the aggregate USD value of the purchases or additional valuation details.